Company ProfilePremium

Medical Developments International Limited

Company Profile Analysis

Ticker: MVP.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Medical Developments International Limited - Company showcase

Year Founded & Workforce

1970

68 Employees

Medical Developments International Limited logo

Medical Developments International Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Medical Developments International Limited Overview

Medical Developments International is a Melbourne-based specialty pharmaceutical and medical device company. Its value rests on one proprietary asset, Penthrox (inhaled methoxyflurane), a fast-acting, non-opioid, self-administered analgesic for trauma and procedural pain, which it manufactures in Scoresby and Springvale, Victoria. Penthrox is the standard of care across Australian ambulance services and is gaining ground in hospital emergency departments. It is sold through partners in the UK, Ireland, the Nordics, France, Switzerland, Canada and more than 20 other markets. A second segment, Respiratory, sells asthma and COPD spacers, peak flow meters, nebulisers and masks in Australia and the US. After a costly FY21–FY24 phase of direct-market expansion, US FDA ambitions, China trials and A$16.4m of impairments, management under CEO Brent MacGregor reset the business to a capital-light, partner-led model with price discipline. The result was EBITDA-positive FY25 and FY26, free cash flow of A$4.2m in FY26, A$21.4m of cash and no debt. The investment case now depends on whether paediatric-label approval in Europe and emergency-department adoption can accelerate volume.


Company's own description (latest annual report, FY26)

In its FY26 Directors' Report, MVP describes its principal activity as providing emergency medical solutions aimed at better patient outcomes in Australia and overseas. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services and sports medicine, and for analgesia during short surgical procedures. It also distributes respiratory devices for people with asthma and COPD [S1]. The standard company boilerplate adds that MVP is a leader in emergency pain relief and respiratory products. It lists Penthrox users as Australian hospitals including emergency departments, ambulance services, the Australian Defence Force and sports medicine, plus analgesia for short procedures such as burns dressing changes, biopsies and dental procedures [S2].

Independent characterisation

MVP is a single-molecule specialty pharma company with a small medical-device distribution business attached. Penthrox generated 74% of FY26 revenue (A$31.6m of A$42.6m) and earned almost all segment profit (Pain Management segment EBIT A$9.4m against Respiratory A$0.7m) [S1]. The business has four structural features:

  1. Vertically integrated manufacturer of a niche, hard-to-replicate product. Methoxyflurane is an old volatile anaesthetic. It was withdrawn from anaesthetic use at high doses in the 1970s because of renal toxicity, but at the low analgesic doses in the 3 mL Penthrox inhaler it has a long safety record in Australian pre-hospital care. MVP makes the drug product and device in-house in Victoria. The regulatory dossier (EU Decentralised Procedure, UK, Canada and others), manufacturing know-how and pharmacovigilance history act as barriers to entry, which matters because patent protection on the molecule itself is not a meaningful moat.

  2. Hybrid commercial model. In Australia MVP sells Penthrox directly to ambulance services, hospitals and procedural/other segments (Australia was 57% of Pain Management revenue in FY26). Everywhere else it sells to exclusive in-country distribution partners at transfer prices. Partners hold the market authorisations or promotional rights and set in-market price. Since 1 May 2025 (Switzerland, Labatec) and 1 July 2025 (France, Ethypharm), the company has had no direct in-market European commercial operation [S3].

  3. Revenue model. Almost entirely product sales, recognised on transfer of control. A small stream of licensing and milestone income comes from upfront partner payments that are deferred and amortised over contract terms: A$0.5–0.6m recognised in FY26, A$0.2m in FY25, and A$0.85m still deferred at 30 June 2026, mainly for Thailand distribution [S1]. There is no subscription or service revenue. Approximate FY26 mix: product sales about 98.6%, amortised milestone/licence income about 1.4% (derived).

  4. Value chain position. MVP sits in manufacturing (Penthrox) and brand-owner distribution (Respiratory devices, which rely on a small number of third-party manufacturers and suppliers [S1]). It has no reimbursement control. In Australia, PBS listing of Penthrox in the Prescriber Bag (Doctor's Bag) supports community/GP access, and a 25% PBS price increase in August 2024 was a major margin driver [S12, S3].

Customer types and end-markets

End-marketCustomer typeProductNotes
Pre-hospital emergency careState ambulance services (Australia), NHS ambulance trusts (UK, via partner), European EMSPenthroxUsed across all Australian ambulance services; Australian ambulance demand +4% in FY26 [S1, S12]
Hospital emergency departmentsPublic and private hospitalsPenthroxMain growth vector. Australian hospital volume +43% FY25, +28% FY26. 244 purchasing hospitals as of FY24 [S4, S3, S1]
Procedural analgesiaDay surgery, women's health, dental, dermatology/cosmetic, burns unitsPenthrox"Other segments" demand +5% in FY26, with growth in procedural segments including women's health [S1]
Defence, sports medicine, mining/remote first aidAustralian Defence Force, sports clubs, industrial first aidPenthroxLegacy Australian niches
Community / primary careGPs, Nurse Practitioners via PBS Prescriber BagPenthroxNurse Practitioners added to PBS Prescriber Bag eligibility in Oct 2025 [S2]
International partnersDistributors (UK/Ireland, Nordics, France, Switzerland, Canada, Middle East, Asia, South Africa)PenthroxOne Pain Management customer exceeded 10% of group revenue in FY26 (A$4.7m), probably a European partner (unnamed) [S1]
Retail pharmacy / consumer respiratoryPharmacy wholesalers, retailers, US distribution partnersRespiratory devicesUS revenue A$6.1m in FY26; Australia A$3.0m [S1]

Strategy

Stated strategy (FY26 annual report themes)

PillarFY27 initiatives
1. Accelerate penetration of PenthroxUnlock value from the paediatric indication in Europe; use health-economic analyses to accelerate hospital adoption; generate additional real-world evidence; strengthen partner engagement
2. Grow Penthrox in new markets and segmentsTargeted entry into selected new markets; evaluate US market-entry planning and alternative pathways; evaluate procedural indication expansion in Europe; broader market assessment
3. Enhance margins and deliver operational efficienciesKeep improving commercial terms to reflect Penthrox's value proposition; disciplined cost management and operational efficiencies

Management describes the nearer-term focus as increasing Penthrox penetration in existing markets, and the longer-term aim as expanding Penthrox into new markets and segments [S1]. The FY27 priorities are organised under three pillars [S1]:

Strategic initiatives in the last 24 months

InitiativeTimingStatus / outcomeSource
Capital-light European model: partner transfer in Switzerland (Labatec) and France (Ethypharm)May / Jul 2025Completed. Lower transfer prices, lower cost to serve, partner inventory build in FY26S3, S1
UK and Ireland distribution extension to end-2027 on improved termsJul 2024Effective from FY25S4
Paediatric label (6+) in UK and EUFiled Aug 2024; approved Aug 2025 to Aug 2026Approved and launched in all targeted marketsS4, S3, S2
Australian ED penetration program: formulary listings (Queensland LAM listing for all public EDs; South Australia formulary), protocol inclusions, clinician engagementFY24–FY26Hospital volume +43% (FY25) and +28% (FY26)S3, S4, S1
Health-economic study of Penthrox in EDsInitiated FY25; published FY26Published in Emergency Medicine Australasia; reports whole-of-department cost and operational savingsS3, S1
MAGPIE paediatric study publicationFY26Published in InjuryS1
PBS Prescriber Bag access for Nurse PractitionersOct 2025EffectiveS2
Pricing: PBS +25% (Aug 2024); Australian price rise for remaining customers (Jul 2025); US Respiratory price increasesFY25–FY26About A$4m (FY25) and about A$1m (FY26) earnings benefit from Australian pricingS3, S1
Cost program: A$3–4m of FY25 efficiencies after A$7.2m of FY24 pricing and efficiency benefitsFY24–FY25Delivered A$4m in cost reductions in FY25S4, S3
Incentive plan reviewFY27In progress; FY26 LTI grants deferredS1
Climate reporting readinessFrom FY28Group 3 entity under Australian mandatory climate disclosuresS1

Guidance and medium-term targets

FY27 qualitative outlook [S1, S2]:

  • Higher in-market Penthrox demand, supported by the European paediatric indication and the health-economic data.

  • Stable Respiratory demand.

  • No repeat of FY26 inventory-stocking benefits.

  • About A$1m of additional amortisation for capitalised European paediatric registration costs.

  • Uncertain earnings impact from Middle East supply-chain disruption and US tariffs.

  • FY27 capex of about A$1.5m.

No quantitative revenue or EBIT guidance and no medium-term financial targets have been published. In FY23 the company estimated US Penthrox in-market revenue potential at US$300–400m five years after launch, but the US program has been paused since July 2024 [S5, S4].

Products & Services

Pain Management segment

ProductDescriptionKey specifications / capabilitiesTarget customersLaunch / latest versionPricing model
Penthrox® (methoxyflurane) inhalation (flagship; "the Green Whistle")Self-administered, fast-acting, non-opioid inhaled analgesic for trauma and procedural pain3 mL methoxyflurane vial with single-use handheld inhaler (with activated carbon chamber to reduce exhaled vapour). Analgesia onset within minutes; patient-controlled intermittent inhalation. Daily and weekly dose ceilings apply under label. Combination product (medicine plus device), so it requires both medicines and device approval in Europe [S3]Ambulance services, hospital EDs, procedural settings, defence, sports medicine, GPs/NPs (PBS Prescriber Bag)In Australian use since the 1970s. UK/EU approval mid-2010s for adults with moderate-to-severe trauma pain. Paediatric extension (age 6+) approved in UK and all EU DCP markets by Aug 2026 [S2]Australia: direct sale at list/contract prices plus PBS-reimbursed Prescriber Bag supply (PBS price +25% Aug 2024). July 2025 increase for remaining customers (about 25% of volume) worth about A$1m in FY26 [S1]. International: transfer prices to partners
Penthrox multi-pack / ambulance and hospital packsPack configurations for institutional buyersConfigurations: n/dAmbulance and hospitals—Contract pricing
Penthrox paediatric indication (label extension)Extension of the European label from 18+ to 6+ supported by the MAGPIE studyMAGPIE study published in Injury (FY26). HPRA approval Aug 2025; device approval Feb 2026; national approvals including UK by Aug 2026 [S3, S9, S2]UK ambulance trusts (removes a barrier to entry in some trusts [S3]), European EDs2025–2026Partner transfer pricing
"Selfie" / NextGen Penthrox delivery device (development)Next-generation inhaler device for ease of useFY21–FY22 disclosures referred to a planned NextGen launch in Australia, UK and Europe by FY24 and to the "Selfie" device reaching development milestones [S13]. Current status: n/d. Not referenced in FY26 priorities—Not launched (status n/d)—

Indications pipeline (stated FY27 priorities): procedural indication expansion in Europe (under evaluation), US market entry "alternative pathways" (under evaluation), and real-world evidence generation [S1].

Respiratory segment

Product lineDescriptionTarget customerNotes
Spacer chambers (brands historically include Space Chamber Plus® and Breath-A-Tech®; current brand list not re-verified)Valved holding chambers used with pressurised metered-dose inhalers; anti-static variants; adult and paediatric sizesPharmacies, hospitals, US retail/pharmacy channelsMain US growth product. MVP claimed continued US spacer market share gains in FY24 (US revenue +37%) and FY25 [S4, S3]. FY26 US revenue -16% on softer demand despite price increases [S1]
Silicone face masksMasks for spacer use by infants, children and adultsPaediatric asthmaSold alongside spacers
Peak flow metersDevices for monitoring expiratory flow in asthma managementPatients, GPs, pharmaciesAustralian market
Portable nebulisersCompact nebuliser unitsPatients, pharmaciesAustralian and Asian markets

The company describes the segment as a leading supplier of spacer chambers, peak flow meters, portable nebulisers and silicone face masks for asthma and COPD patients. It sells into Australia, the US, Europe and Asia through leading distributors [S1].

Pricing model: wholesale/distributor pricing. US pricing initiatives were used in FY26 to offset tariff pressure [S1].

Discontinued / exited portfolios

PortfolioExit dateNotes
Veterinary productsFY22Segment exited [S6]
Non-core medical equipment linesFY22Exit of unprofitable, non-core medical lines announced with H1 FY22 results [S13]
Continuous-flow manufacturing program (with CSIRO)FY22Program concluded. A CSIRO options reserve of A$1.866m remains in equity [S6, S1]
US Penthrox Phase III / NDA programPaused Jul 2024Assets impaired (part of A$16.4m) [S4]
China Penthrox programFY23Discontinued; termination revenue recognised [S5]

Financial Narrative

Income statement: notes and sources

Source: FY26 Remuneration Report five-year performance table [S1]; FY25–FY26 P&L [S1]. FY23 revenue excludes A$18.9m contract termination revenue (A$18.5m China), which is included in reported EBIT [S1]. FY24 reported EBIT includes A$21.5m of underlying adjustments (A$16.4m impairments; A$5.1m non-cash CEO remuneration transition expense), and FY24 NPAT includes a A$15.0m non-cash tax charge from derecognising tax losses [S4].

Margin profile

Notes: Company gross margin of 74% in FY24 is reported as "up 5ppts", which implies about 69% in FY23 [S12]. The company did not restate a gross margin figure in FY25–FY26 releases. The derived proxy uses "raw materials and consumables used" (A$11,896k FY26; A$10,812k FY25) and excludes manufacturing labour, so it is not comparable with company-defined gross margin. FY23 net margin is distorted by termination revenue.

Revenue CAGR FY22–FY26: 18.0% (A$21.9m to A$42.6m, derived). FY24–FY26 CAGR: 13.3% (derived).

FY26 vs FY25 expense structure [S1]

Commentary: The FY22–FY24 period was an expensive build-out. It included direct commercial capability in Europe (France, Switzerland), a US Penthrox regulatory program, a China clinical program and Australian hospital investment, and underlying EBIT losses peaked at A$18.2m in FY23. The inflection came in FY24–FY25 under the "pricing and efficiency" program. FY24 delivered A$7.2m of pricing and efficiency benefits and a 5ppt gross-margin uplift [S4]. FY25 added a further A$4m from pricing (the August 2024 PBS increase and better UK/Ireland terms) and A$4m of cost reductions [S3]. Those changes produced an A$11.6m EBIT turnaround to breakeven. FY26 EBIT was only A$0.3m better, despite A$3.5m more revenue, for three reasons: a A$2.5m adverse FX swing, a deliberate increase in medical and commercial spend, and lower average European selling prices after the shift to partner supply [S1]. Management excluded partner-stocking timing benefits from STI calculations, which suggests that FY26 EBIT on a "clean" basis was weaker than reported [S1].

Balance sheet

Sources: S1 balance sheet, changes in equity (FY24 closing equity A$45,734k) and Note 2.4 (FY24 opening PP&E and intangibles); S12 (cash A$9.7m at 30 June 2024). Earlier cash reference points: A$15.5m (30 Jun 2020), A$36.2m (30 Jun 2021), A$28.3m (31 Dec 2021), and about A$49m pro forma after the August 2022 raise [S13, S6].

Balance sheet commentary: MVP has no financial debt. Its only interest-bearing obligations are property leases of A$1.7m. Equity is A$55.8m, against accumulated losses of A$62.1m and contributed equity of A$115.0m, which shows how much capital the FY21–FY24 investment cycle consumed [S1]. Intangibles of A$21.2m are dominated by A$14.6m of capitalised European registration costs (including the paediatric dossier, which starts amortising at about A$1m a year in FY27) and A$3.8m of Pain Management goodwill. The Pain Management CGU carrying value (A$3.8m goodwill plus A$16.1m other intangibles) was a Key Audit Matter for Deloitte [S1]. Unused Australian tax losses total A$16.0m, of which only A$1.6m is recognised as a DTA [S1]. Working capital fell A$5.2m in FY26 as inventory dropped A$2.5m (lower Respiratory demand and the shift away from holding French stock) [S1].

Cash flow

Notes: FY26 FCF of A$4.2m is company-reported [S1, S2]. FY25 is derived from the stated A$5.8m FY26 improvement. FY24 is derived from the stated A$12.9m FY25 improvement. FY23 is derived from the A$10.2m FY24 improvement; S4 also describes this as +42%, which implies about -A$24.3m, so FY23 is approximate. The August 2022 A$30m raise fell in FY23. The August 2024 A$10m raise fell in FY25 (gross A$10,014k, costs A$736k) [S1, S6]. Employee trust purchases are on-market purchases to satisfy incentive awards, not capital-return buybacks [S1].

FY26 cash-flow bridge (A$000): EBITDA 2,900, plus non-cash items 946, plus working-capital release 2,173, less other movements 558, plus net interest 289, gives operating cash flow of 5,750. After capex 795, leases 319 and the employee share trust 479, company-defined FCF was about 4.2m. A A$7.0m term deposit (5.1%, maturing November 2026) was moved out of cash, so reported cash fell A$3.5m even though total liquidity rose [S1].

Ratios

All ratios are derived from S1. Negative net debt/EBITDA indicates a net cash position. Inventory and payable days use raw materials and consumables as a COGS proxy because the company does not disclose cost of goods sold, so they overstate true days. Read them for direction only. The ratios point to a business that is liquid and unlevered but earns very low returns on its capital base: ROE is about 1% on A$55.8m of equity.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProductsRegions of operation (per Note 1.1)

Pain Management

Manufacture and sale of Penthrox

Penthrox (methoxyflurane 3 mL with inhaler; multiple pack configurations)

Australia, Europe, United Kingdom, Middle East, Canada, Asia, South Africa

Respiratory

Sale of respiratory devices for asthma and COPD

Spacer chambers, peak flow meters, portable nebulisers, silicone face masks

Australia, USA, Europe, Canada, Asia, United Kingdom

Other (unallocated)

Corporate overheads and foreign-exchange gains/losses

——

Revenue by Segment

SegmentFY2024FY2025FY2026

Pain Management revenue (AUD K)

21,30026,19031,620

Respiratory revenue (AUD K)

11,90012,86610,948

Group revenue (AUD K)

33,14939,05642,568

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

Segment metricFY2024FY2025FY2026

Pain Management YoY revenue growth (%)

4.023.020.7

Respiratory YoY revenue growth (%)

1.09.0-14.9

Pain Management share of group revenue (%)

64.367.174.3

Respiratory share of group revenue (%)

35.932.925.7

Pain Management segment EBITDA (AUD K)

—8,82111,376

Respiratory segment EBITDA (AUD K)

—7061,003

Other / corporate EBITDA (AUD K)

—-6,372-9,479

Pain Management segment EBIT (AUD K)

—6,2879,420

Respiratory segment EBIT (AUD K)

—430702

Other / corporate EBIT (AUD K)

—-6,765-9,907

Pain Management EBITDA margin (%)

—33.736.0

Respiratory EBITDA margin (%)

—5.59.2

Pain Management EBIT margin (%)

—24.029.8

Respiratory EBIT margin (%)

—3.36.4

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue, underlying (AUD K)

21,94332,33733,14939,05642,568

Revenue growth (%)

34.447.02.517.89.0

Underlying EBITDA (AUD K)

-11,724-15,133-8,2373,1552,900

Underlying EBIT (AUD K)

-14,669-18,246-11,631-48215

Reported EBIT (AUD K)

-15,850-7,957-33,142-48215

Profit before tax (AUD K)

———168504

Income tax benefit / (expense) (AUD K)

———-74122

Statutory NPAT (AUD K)

-12,407-5,609-40,99294626

Basic EPS (A$ cents)

-17.41-6.66-47.500.090.56

Diluted EPS (A$ cents)

———0.080.53

Dividends per share (A$ cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin, company-reported (%)

—6974——

Revenue less raw materials and consumables, derived (%)

———72.372.1

Underlying EBITDA margin (%)

-53.4-46.8-24.88.16.8

Underlying EBIT margin (%)

-66.9-56.4-35.1-0.10.5

Net margin on underlying revenue (%)

-56.5-17.3-123.70.21.5

Income Statement

Line itemFY2025FY2026

Raw materials and consumables (AUD K)

10,81211,896

Employee benefits expense (AUD K)

14,77116,006

Distribution expenses (AUD K)

2,1881,602

Regulatory and registration expenses (AUD K)

1,9011,329

Occupancy, selling and administration (AUD K)

7,9417,993

Other gains / (losses), mainly FX (AUD K)

1,626-905

Depreciation and amortisation (AUD K)

3,2032,685

Interest and other income (AUD K)

377417

Finance costs (AUD K)

7565

Balance Sheet and Per-Share Data

MetricFY2024FY2025FY2026

Cash and cash equivalents (AUD K)

9,73517,83714,368

Term deposits / other financial assets (AUD K)

007,000

Total cash incl. term deposit (AUD K)

9,73517,83721,368

Trade and other receivables (AUD K)

—7,6526,699

Inventories (AUD K)

—9,4506,953

Plant and equipment incl. right-of-use (AUD K)

10,1628,9387,729

Goodwill (AUD K)

3,8083,8083,808

Goodwill and other intangibles (AUD K)

22,85721,91821,237

Total assets (AUD K)

—66,39664,600

Borrowings, short-term (AUD K)

000

Borrowings, long-term (AUD K)

000

Lease liabilities, total (AUD K)

—1,9901,667

Total liabilities (AUD K)

—11,2928,793

Total equity (AUD K)

45,73455,10455,807

Net cash incl. term deposit, less leases (AUD K)

—15,84719,701

Working capital, current assets less current liabilities (AUD K)

—27,71629,436

NTA per share (A$ cents)

—29.530.7

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD K)

———-435,750

Capex, plant and equipment (AUD K)

———443481

Capex, intangibles (AUD K)

———597314

Lease repayments (AUD K)

———296319

Free cash flow, company definition (AUD K)

—-24,700-14,500-1,6004,200

Dividends paid (AUD K)

00000

Share buybacks, employee trust purchases (AUD K)

———304479

Equity raised, gross (AUD K)

—30,000010,0140

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE, on average equity (%)

0.21.1

ROA, on average assets (%)

—1.0

ROIC, NOPAT at 25% over equity less net cash (%)

-0.10.4

Current ratio (x)

4.545.77

Debt to equity, incl. leases (x)

0.040.03

Net debt to EBITDA (x)

-5.0-6.8

Interest coverage, EBIT over finance costs (x)

-0.63.3

Asset turnover, revenue over average assets (x)

—0.65

Receivable days (days)

7257

Inventory days, on raw-material cost proxy (days)

319213

Payable days, on raw-material cost proxy (days)

219149

Cash conversion cycle, proxy (days)

172121

Revenue by Region

RegionFY2024FY2025FY2026

Australia (AUD K)

—18,82820,874

Europe incl. UK (AUD K)

—9,3149,614

United States (AUD K)

—7,2776,135

Rest of World (AUD K)

—3,6375,945

Total (AUD K)

33,14939,05642,568

Revenue by Region (FY2025–FY2026)

Segment and regionFY2025FY2026

Pain Management, Australia (AUD K)

15,42717,909

Pain Management, Europe (AUD K)

8,0739,019

Pain Management, United States (AUD K)

00

Pain Management, Rest of World (AUD K)

2,6904,692

Respiratory, Australia (AUD K)

3,4012,965

Respiratory, Europe (AUD K)

1,241595

Respiratory, United States (AUD K)

7,2776,135

Respiratory, Rest of World (AUD K)

9471,253

Geographic Revenue

RegionFY2025 share (%)FY2026 share (%)FY26 YoY growth (%)

Australia

48.249.010.9

Europe

23.822.63.2

United States

18.614.4-15.7

Rest of World

9.314.063.5

Markets

MarketFY2024FY2025FY2026

Australian hospital segment Penthrox volume growth (%)

304328

Australia total Penthrox volume growth (%)

3—9

Australia ambulance volume growth (%)

——4

European in-market Penthrox volume growth (%)

—1518

UK and Ireland in-market volume growth (%)

3—20

France in-market volume growth (%)

——11

Nordic in-market volume growth (%)

42—19

US Respiratory revenue growth (%)

37—-16

Share Price and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at period end (AUD)

1.460.780.390.550.39

Annual price change (%)

—-46.6-50.041.0-29.1

Valuation Multiples

MultipleMVP

Market capitalisation (AUD Mn)

51.3

Enterprise value: market cap less cash and term deposit plus leases (AUD Mn)

31.6

P/E, FY26 basic EPS 0.56c (x)

81

EV / EBITDA, FY26 (x)

10.9

EV / Sales, FY26 (x)

0.74

P / Book (x)

0.92

P / NTA, NTA 30.7c (x)

1.48

Analyst Ratings & Targets

Broker / sourceRatingTarget (AUD)Date

Bell Potter

Positive (target implies about 100% upside)

1.00

Aug 2026 [S15]

TipRanks-aggregated latest rating

Buy

0.80

Aug–Sep 2025 [S15]

Consensus

n/d (Market Index notes no major-broker consensus compilation)

—2026

Capital Markets

ItemStatus

Dividend history

No dividends declared for FY22–FY26 [S1]. Small dividends were paid before the investment phase (FY20 yield cited at about 0.6–0.7%) [S15]

Dividend policy

None stated; capital prioritised for Penthrox growth

Buyback authorisations

None. Only on-market purchases by the employee share trust (A$0.48m in FY26) [S1]

Credit ratings (Moody's, S&P, Fitch)

Not rated

Debt maturity profile

No borrowings. Lease liabilities of A$1.667m (current A$0.343m; non-current A$1.324m) [S1]

Dilution overhang

2.30m unvested KMP performance rights plus CSIRO options; diluted share count 117.1m [S1]

Analyst Conclusions

Management guidance (FY27) [S1, S2]

  • Higher in-market Penthrox demand (paediatric indication; health-economic data).

  • Stable Respiratory demand.

  • No repeat of FY26 partner inventory-stocking benefits.

  • About A$1m of incremental amortisation from capitalised European paediatric registration costs.

  • Middle East supply-chain and US tariff impacts uncertain.

  • Capex of about A$1.5m.

  • No quantitative EBIT or revenue guidance.

Consensus expectations

n/d. Coverage is limited to a small number of brokers, and no published consensus revenue or EPS for FY27 was verifiable.

Bull case

  1. The paediatric label is a volume step-change in the UK and Europe. The UK is the largest ex-Australia market. The partner already has listings in over 70% of hospital trusts, and the paediatric label removes a stated barrier to some ambulance trusts [S4, S3]. European in-market volume already grew 18% before the label took effect [S1].

  2. Operating leverage on a high-margin core. Pain Management converts about 36% of revenue into EBITDA. If corporate costs stay near A$9–10m, each extra A$5m of Penthrox revenue could add roughly A$1.8m of EBITDA, a meaningful increase on a A$2.9m base (analyst estimate).

  3. Optionality at a low valuation. With EV of about A$32m (0.74x sales) and an A$21m cash buffer, a US partnering deal through "alternative pathways", against the company's own US$300–400m US potential estimate, or new-market entries would be value-accretive without needing a capital raise [S5, S1].

Bear case

  1. FY26 earnings quality is weaker than reported. Partner stocking, a one-off US tariff refund and lower D&A supported FY26, and the board itself excluded the stocking timing benefits. FY27 also absorbs about A$1m of new amortisation [S1, S2].

  2. Growth may be structurally capped. European revenue grew only 12% against 18% volume growth because of lower transfer prices. Australian ambulance (+4%) is mature. Respiratory is shrinking (-15%) and tariff-exposed [S1].

  3. Track record of capital consumption. Accumulated losses are A$62m, the company has raised about A$40m since 2022, three successive LTI tranches have failed or are failing, and several international strategies (US, China, direct Europe) have been abandoned [S1, S4, S5].

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Late Oct 2026Q1 FY27 Appendix 4C: first read on European paediatric uptake and stocking reversal
Oct–Nov 20262026 AGM: Chair Fladrich's first AGM; incentive-plan review signals
Nov 2026Maturity of the A$7.0m term deposit (cash reclassification only)
Ongoing FY27Australian hospital volume growth (sustaining 20%+); NHS ambulance trust adoption; new-market entries
Feb 2027H1 FY27 results: EBIT trajectory after stocking non-recurrence and new amortisation
FY27Any US pathway or partnering announcement; procedural-indication decisions in Europe
FY27US tariff regime and Respiratory demand; Middle East logistics costs
End-2027UK and Ireland distribution agreement expiry and renewal terms

Analyst verdict

Medical Developments International has completed a credible operational turnaround but has not yet proved it is a growth company. Between FY23 and FY26 management moved the business from an A$18.2m underlying EBIT loss to modest profit. It did so by repricing Penthrox in Australia, extracting better partner terms, exiting direct European operations, and abandoning capital-hungry ventures in the US and China. The balance sheet is now clean, with A$21.4m of cash, no debt and a self-funding operation. That removes the dilution risk that dominated the share register from 2022 to 2024.

The core asset is valuable. Penthrox has a 36% segment EBITDA margin, decades of safety data and newly expanded paediatric labelling in its most important export market. Clinical and health-economic evidence for emergency-department use is accumulating, and Australian hospital volumes have grown 28–43% a year for three years.

Even so, group profitability is barely positive. A corporate cost base of about A$9.5m absorbs most segment profit, and FY26 results were flattered by partner stocking, a tariff refund and favourable amortisation. FY27 begins with explicit headwinds: no repeat of stocking, about A$1m of new amortisation, and tariff and Middle East uncertainty. Respiratory is a drag that management has not fixed.

At about A$0.45 and an enterprise value of about A$32m (0.7x sales; about 11x a depressed EBITDA), the market is assigning little value to the paediatric opportunity or any US optionality. The equity is therefore an asymmetric but execution-dependent proposition. If in-market European volume growth accelerates beyond 20% in FY27 and Australian hospital momentum continues, operating leverage should become visible and support a re-rating toward broker targets (A$0.80–1.00). If FY27 EBIT turns negative once stocking reverses, the stock is likely to remain a value trap.

Overall stance: speculative positive. Thesis validation hinges on the H1 FY27 result (February 2027).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundFY26 statutory total (AUD)

Brent MacGregor

Chief Executive Officer

CEO since 2021 (exact start date n/d)

Education and age: n/d

1,213,519

Anita James

Chief Financial Officer

n/d (KMP for full FY25 and FY26)

Education and age: n/d

656,626

Tara Eaton

Company Secretary and General Counsel

Since 8 Aug 2022

Former General Counsel, Australian Red Cross; Legal and Compliance Director, Gilead Sciences ANZ; Legal Director, Merck & Co; earlier at Minter Ellison and Clayton Utz. Qualifications: B.As, LLB, LLM, GradDip (Applied Corp Gov), GAICD

Not KMP

Directors' Remuneration

ComponentMacGregor FY2025MacGregor FY2026James FY2025James FY2026

Base salary (AUD)

620,132645,314360,849373,487

STI cash (AUD)

150,778102,34680,05385,390

Other benefits (AUD)

48,54964,15600

Other long-term benefits (AUD)

11,08116,9112,8555,297

Superannuation (AUD)

29,93230,00041,49844,818

STI equity (AUD)

150,777102,34580,05385,389

LTI, share-based (AUD)

252,447252,44781,49662,245

Total statutory (AUD)

1,263,6961,213,519646,804656,626

Board of Directors

NameRoleAppointedIndependentCommitteesBackgroundOther listed boardsFY26 fees (AUD)

Mark Fladrich (BPharm, MBA, GAICD)

Non-Executive Chair (since 1 Dec 2025)

2025 (NED before becoming Chair; exact date n/d)

Yes

ARC, PCC, CDC

Over 30 years in pharma. Former Chief Commercial Officer at Grünenthal, where he expanded the US presence alongside relaunch of a non-opioid chronic pain product. 23 years at AstraZeneca, including VP Global Strategic Marketing and Country President for Germany and Australia/NZ. Also Allergan and Faulding

QBiotics (May 2024 – Nov 2025)

80,417

Leon Hoare

NED; Chair of People and Culture Committee

27 Sep 2013

Yes (tenure about 13 years)

PCC (Chair)

Managing Director, Lohmann & Rauscher ANZ to Dec 2025. 24 years at Smith & Nephew, including MD ANZ and President of Asia-Pacific Advanced Wound Management

PolyNovo (since 2016)

60,000

Christine Emmanuel-Donnelly

NED

26 May 2020

Yes

ARC

Intellectual property and business development executive. Former Executive Manager of BD and Commercial at CSIRO; patent attorney

Chair of ImpediMed; NED of PolyNovo

60,000

Dr Russell Basser (MD, FRACP)

NED

1 Sep 2023

Yes

PCC

Medical oncologist; 21 years at CSL, including Chief Medical Officer and SVP R&D at CSL Seqirus

Starpharma (since 2023)

60,000

Paul Townsend (BBusAcc, FCA, GAICD)

NED

30 May 2025

Yes

ARC, CDC

ASX CFO experience at Nufarm, Asaleo Care and Pacific Hydro; also Monash University

—60,000

Gordon Naylor (former)

Former Chair

Resigned 1 Dec 2025

——

Ex-CSL senior executive; about five years on the board, mostly as Chair

—39,583

Major Shareholders

Holder categoryShares% of 112.66mSource

Non-executive directors (combined)

304,8090.27

S1

CEO B. MacGregor

649,2510.58

S1

CFO A. James

208,3170.18

S1

Unvested performance rights (CEO and CFO)

2,302,357

2.04 (potential)

S1

Competitive Landscape

Key Competitors

#Competitor / alternativeCompanySettingRelative positioning vs Penthrox
1

Nitrous oxide/oxygen 50:50 (Entonox)

Linde plc (BOC)

Ambulance, ED, labour, procedures

Entrenched and cheap per use, but needs cylinders and equipment and has environmental (greenhouse) and occupational exposure concerns. Penthrox is more portable

2

Nitrous oxide/oxygen (Kalinox and others)

Air Liquide

France and Europe procedures

Strong in France; a competitive barrier to Penthrox's French penetration

3

Intravenous / intramuscular morphine and generic opioids

Multiple generic manufacturers

ED, ambulance

Standard of care. Needs IV access and carries opioid risks. Penthrox's non-opioid profile and speed are its differentiators

4

Intranasal fentanyl (e.g. Instanyl; generics)

Multiple (originally Takeda/Nycomed)

Pre-hospital, paediatric ED

Direct competitor in paediatric pre-hospital care, an area the new Penthrox paediatric label now contests

5

Ketamine (low-dose, IV/IN)

Generic manufacturers

ED, pre-hospital, military

Growing use for trauma analgesia

6

Sublingual sufentanil (Zalviso / Dsuvia)

—

Acute pain

Non-invasive opioid alternative; niche

7

IV paracetamol / IV ibuprofen / NSAIDs

Multiple (B. Braun, Fresenius Kabi and generics)

ED

Adjunct or alternative for moderate pain

8

Methoxyflurane generics / follow-ons

None known to be approved in MVP's core markets

—

Barrier: manufacturing know-how and regulatory dossiers. Any generic entry is a key long-term risk

9

AeroChamber Plus family

Trudell Medical International (private, Canada)

Valved holding chambers

Global category leader, including the US. MVP is a share-gainer from a small base

10

OptiChamber Diamond

Philips Respironics

Valved holding chambers

Major US and global player

11

Vortex spacers, PARI nebulisers

PARI GmbH (private)

Spacers, nebulisers

Strong in Europe

12

Able Spacer, Mini-Wright peak flow meters

Clement Clarke International (UK)

Spacers, peak flow meters

UK/Europe

13

Omron nebulisers

Omron Healthcare

Nebulisers

Consumer nebuliser leader

Competitor Detail

MetricMVP (FY26)

Revenue

A$42.6m

Revenue growth

9.0%

EBITDA margin

6.8%

EBIT margin

0.5%

R&D intensity

n/d (capitalised about 0.7% of revenue)

Recent Developments

--

Company Snapshot

68

Employees

1970

Founded

Victoria, Australia

Headquarters

SWOT Analysis

Strengths

  • Franchise product with pricing power: PBS price +25% (Aug 2024); FY25 pricing contribution about A$4m; FY26 Australian price increase about A$1m [S12, S3, S1]
  • Accelerating hospital adoption in Australia: Hospital volume +30% (FY24), +43% (FY25), +28% (FY26) [S4, S3, S1]
  • Expanded label in Europe: Paediatric (6+) approval and launch in UK and all EU DCP markets, Aug 2025 to Aug 2026 [S2]
  • Clean balance sheet: A$21.4m cash and term deposit; zero borrowings; lease liabilities only A$1.7m [S1]
  • Self-funding operations: Operating cash flow A$5.75m and FCF A$4.2m in FY26 [S1]
  • High-margin core segment: Pain Management EBITDA margin 36.0% and EBIT margin 29.8% in FY26 [S1]
  • Growing evidence base: MAGPIE published in Injury; ED health-economic study in Emergency Medicine Australasia [S1]
  • Experienced pharma-commercial board: Chair ex-Grünenthal CCO and AstraZeneca; directors ex-CSL CMO and ex-Nufarm CFO [S1]

Weaknesses

  • Single-product concentration: Penthrox is 74% of revenue and about 92% of positive segment EBIT [S1]
  • Thin group profitability: EBIT A$0.2m (0.5% margin); NPAT A$0.6m on A$42.6m revenue [S1]
  • Corporate overhead heavy for the company's size: "Other" EBIT -A$9.9m (FY26), larger than Pain Management EBIT growth [S1]
  • Partner-dependent revenue quality: FY26 RoW +74% and European revenue partly from partner stocking; the board excluded these timing benefits for STI [S1]
  • Respiratory under-performance: Revenue -15%; 27% below internal target; US -16% [S1]
  • Lower European realised prices under the capital-light model: Transfer prices into France and Switzerland fell after partner transition [S1]
  • Poor long-term shareholder returns and a capital-consumption history: Accumulated losses A$62.1m; share price A$1.46 (FY22) to A$0.39 (FY26); A$40m of equity raised in FY23–FY25 [S1]

Opportunities

  • Paediatric European demand: Label now approved; management expects benefits in future periods; addresses a UK ambulance-trust entry barrier [S2, S3]
  • Health-economic-led hospital adoption internationally: FY27 priority to use the analyses to accelerate hospital adoption [S1]
  • US re-entry through alternative pathways: Company's earlier US$300–400m in-market potential estimate; "alternative pathways" under evaluation [S5, S1]
  • Procedural indications in Europe: Under evaluation [S1]; Australian procedural and women's-health use already growing [S1]
  • New markets using existing approvals: "Targeted entry into select new markets" [S1]
  • Nurse-led prescribing: PBS Nurse Practitioner Prescriber Bag access from Oct 2025 [S2]
  • Tax-loss shield: A$14.4m of unrecognised Australian tax losses available against future profits [S1]

Threats

  • US tariffs on Respiratory imports: FY27 outlook flags uncertainty; FY26 benefited from a tariff refund that may not recur [S1]
  • Middle East supply-chain disruption: Explicitly flagged in FY27 outlook [S1]
  • FX volatility: FY26 FX loss A$0.9m vs A$1.6m gain in FY25, an A$2.5m swing against EBIT of A$0.2m [S1]
  • Impairment risk on intangibles: Pain Management CGU (A$19.9m) is a Key Audit Matter; A$16.4m impairment taken in FY24 [S1, S4]
  • Regulatory conservatism on methoxyflurane: US program halted twice historically (earlier FDA suspension and the 2024 pause) [S4]
  • Supplier concentration: Reliance on a small number of third parties for a substantial portion of products [S1]
  • Partner contract renewal risk: UK and Ireland agreement runs to end-2027 [S4]

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 May 2025Labatec takes over Penthrox distribution in Switzerland S3Exit from direct Swiss operations
26 May 2025FY25 LTI performance rights granted (CEO 1,229,338; CFO 303,114; baseline A$0.453) S1Executive alignment to share-price recovery
30 May 2025Paul Townsend appointed NED S1Strengthens audit and finance skills
1 Jul 2025Ethypharm takes over Penthrox supply in France S3, S1Completes European capital-light transition
Jul 2025Penthrox price increase for Australian customers without a FY25 rise (about 25% of volume) S1About A$1m FY26 earnings benefit
Aug 2025HPRA approves paediatric (6+) extension of Penthrox indication under EU DCP S3Major label expansion milestone
21 Aug 2025FY25 results: revenue A$39.1m (+18%); NPAT A$0.1m; EBIT improved A$11.6m; cash A$17.8m S3First profit after FY22–FY24 losses
21 Aug 2025FY26 outlook flags likely softer EBIT because of growth investment and the France/Switzerland transition S3Expectation reset
8 Sep 2025Notice of 2025 AGM (hybrid, 10 Oct 2025) S15Governance
10 Oct 20252025 AGM: all resolutions passed S11Shareholder support
Oct 2025PBS adds Nurse Practitioners to Penthrox Prescriber Bag criteria S2Broader Australian access
20 Oct 2025Market cap about A$80.6m at A$0.72 (TipRanks), roughly the 12-month share-price high S15Sentiment peak
1 Dec 2025Chair Gordon Naylor resigns; Mark Fladrich appointed Chair S1Leadership transition to a pain-pharma commercial specialist
30 Jan 2026Q2 FY26 4C: positive operating cash flow; European in-market volume +10% in quarter; device approval expected by end-Feb 2026 S9Cash-flow progress
Feb 2026Paediatric device approval received S14Clears combination-product requirement
19 Feb 2026H1 FY26 results: revenue +8% to A$21.6m; Pain Management +18%; underlying EBIT -A$0.3m; NLAT A$0.2m; cash A$16.9m S10H2-weighted year; investment phase
FY26 (date n/d)MAGPIE paediatric study published in *Injury* S1Peer-reviewed evidence
FY26 (date n/d)Health-economic study published in *Emergency Medicine Australasia* S1Hospital value dossier
24 Apr 2026Q3 FY26 4C: positive cash flow; cash A$18.7m; YTD Penthrox revenue +A$4.9m; UK paediatric approval expected Aug 2026 S8Momentum
2 Jun 2026Change in substantial holding notice S15Register change (holder n/d)
3 Jun 2026Becoming a substantial holder notice S15New substantial holder (identity n/d)
Jun – Jul 2026Notifications of cessation of securities (lapsed performance rights) S1, S15Housekeeping (CFO forfeited 84,930 rights in FY26)
24 Jul 2026Q4 FY26 4C: positive FCF for Q4 and FY26; Q4 revenue A$10.5m; Q4 operating cash flow A$3.0m; cash plus term deposit A$21.4m; FY26 EBIT expected to improve modestly on FY25 S7Pre-result positive update
By Aug 2026Paediatric label approved and launched in UK and all European markets S2Addressable market expansion
12 Aug 2026Results date and webcast notice S15Disclosure
20 Aug 2026FY26 results: revenue A$42.6m (+9%); NPAT A$0.6m; EBIT A$0.2m; FCF A$4.2m; no dividend; FY27 outlook flags stocking non-recurrence and Middle East and tariff uncertainty S1, S2Breakeven sustained; quality-of-earnings debate
20 Aug 2026Refund of US tariffs paid in FY25–FY26 recognised in Respiratory segment S1One-off support to Respiratory EBIT
25 Aug 2026Bell Potter price target A$1.00 (Motley Fool report; shares about A$0.50; market cap A$56.3m) S15Broker support
27 Aug 2026Share price A$0.455 (FNArena) S15Post-result de-rating
7 Sep 2026FY26 Annual Report lodged S15Disclosure
Sep 2026FY24 LTI tranche testing window (baseline A$0.898) S1Likely nil vesting (analyst inference)
Oct 2026 (expected)Next catalysts

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment: Pain Management revenue rose from AUD 21.3 Mn in FY2024 to AUD 31.6 Mn in FY2026.
Medical Developments International Limited — Revenue by Segment
Series (AUD Mn)FY2024FY2025FY2026
Pain Management revenue21.326.231.6
Respiratory revenue11.912.910.9
Group revenue33.139.142.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.